CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 123 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2023. The put-call ratio across all filers is 1.64 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $63,314,313 | -28.1% | 2,900,335 | +4.8% | 0.00% | -20.0% |
| Q2 2023 | $88,003,526 | +15.0% | 2,768,277 | -11.8% | 0.01% | +25.0% |
| Q1 2023 | $76,525,723 | -64.6% | 3,137,586 | -54.2% | 0.00% | -33.3% |
| Q4 2022 | $215,999,798 | +181.1% | 6,848,440 | +151.8% | 0.01% | +20.0% |
| Q3 2022 | $76,847,000 | +20.4% | 2,719,272 | +12.6% | 0.01% | +25.0% |
| Q2 2022 | $63,839,000 | -15.7% | 2,414,474 | +11.7% | 0.00% | 0.0% |
| Q1 2022 | $75,695,000 | +5.3% | 2,162,096 | -2.5% | 0.00% | +33.3% |
| Q4 2021 | $71,883,000 | +12.7% | 2,217,248 | +2.6% | 0.00% | 0.0% |
| Q3 2021 | $63,772,000 | +90.1% | 2,161,772 | +65.1% | 0.00% | +50.0% |
| Q2 2021 | $33,550,000 | +162.2% | 1,309,519 | +40.5% | 0.00% | +100.0% |
| Q1 2021 | $12,798,000 | – | 932,136 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,965,701,000 | 23.51% |
| Affinity Asset Advisors, LLC | 225,000 | $7,295,000 | 2.65% |
| Perceptive Advisors | 10,173,454 | $329,822,000 | 2.54% |
| Artal Group S.A. | 1,500,000 | $48,630,000 | 1.32% |
| Rock Springs Capital Management LP | 1,648,435 | $53,442,000 | 1.24% |
| RTW INVESTMENTS, LP | 666,666 | $21,613,000 | 0.32% |
| BOULDER HILL CAPITAL MANAGEMENT LP | 8,900 | $289,000 | 0.28% |
| EAM Investors, LLC | 39,907 | $1,294,000 | 0.21% |
| FEDERATED HERMES, INC. | 3,113,333 | $100,934,000 | 0.19% |
| Alkeon Capital Management | 1,909,035 | $61,891,000 | 0.12% |